title: [Efficacy and safety of dotarizine vs. cinnarizine in the symptomatic treatment of acute balance disorders (common vertigo)].
abstract: One hundred and ten adult patients suffering from peripheral vertigo were treated in a multifactorial double-blind randomized clinical trial with dotarizine (50 mg b.i.d.) or cinnarizine (75 mg b.i.d.). There was a 60 days clinical follow-up. Results showed that dotarizine was significantly active against the vertigo attacks and its associated symptoms (mainly neurovegetative). The global superiority of dotarizine was confirmed by statistically significant differences between treatments in the improvement of the severity of vertigo, hearing loss in audiometries, global relief of symptoms, disability produced by crises and global assessment by the investigators themselves. No clinically significant unwanted effects were seen in either group on blood pressure, heart rate or analytical parameters. No serious adverse effects to dotarizine were reported. This study confirms the value of dotarizine in the treatment of peripheral vertigo.
authors.affiliation: Servicio de O.R.L., Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona.
authors.forename: E
authors.initials: E
authors.lastname: Perelló
authors.forename: E
authors.initials: E
authors.lastname: Esteller
authors.forename: A
authors.initials: A
authors.lastname: Colls
authors.forename: C
authors.initials: C
authors.lastname: Magriñá
authors.forename: H
authors.initials: H
authors.lastname: Massegur
authors.forename: J
authors.initials: J
authors.lastname: Lluansí
authors.forename: J F
authors.initials: JF
authors.lastname: Casamitjana
authors.forename: X
authors.initials: X
authors.lastname: Lao
authors.forename: F
authors.initials: F
authors.lastname: Roca-Ribas
authors.forename: N
authors.initials: N
authors.lastname: Miró
authors.forename: J
authors.initials: J
authors.lastname: Prades
authors.forename: E
authors.initials: E
authors.lastname: Herrero
authors.forename: O
authors.initials: O
authors.lastname: Molá
authors.forename: J
authors.initials: J
authors.lastname: Torres
authors.forename: M
authors.initials: M
authors.lastname: Márquez
authors.forename: J A
authors.initials: JA
authors.lastname: Ortiz
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002936:Cinnarizine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D014717:Vertigo / Q000188:drug therapy*
chemical_list: D001559:Benzhydryl Compounds; D002121:Calcium Channel Blockers; D006634:Histamine H1 Antagonists; D010879:Piperazines; D012702:Serotonin Antagonists; D002936:Cinnarizine; C083946:dotarizine
vernacular_title: Eficacia y seguridad de dotarizina frente a cinarizina en el tratamiento sintomático de los trastornos agudos del equilibrio (vértigo común).